ECYT News 18.15 Endocyte Inc (ECYT)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Endocyte Inc (ECYT) 18.15 $ECYT

5 Unlikely Companies Bucking the Biotech Sell-Off
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 15, 11:05AM CDT
Over the past month biotech stocks have been absolutely bludgeoned, with the SPDR S&P Biotech ETF down 22.4%. I've offered my two cents on the subject previously and surmised the the dramatic fall is based on some combination of unrealistic...

How Endocyte (ECYT) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 7:36AM CDT
Endocyte is seeing solid earnings estimate revision activity and also has a great company from a Zacks Industry Rank perspective

Endocyte (ECYT) Showing Signs Of A Dead Cat Bounce Today
at The Street - Mon Apr 07, 9:25AM CDT
Trade-Ideas LLC identified Endocyte (ECYT) as a "dead cat bounce" (down big yesterday but up big today) candidate

Product Launches, Acquisitions, Closed Offerings, Divestitures, and Financial Results - Analyst Notes on Dr. Reddy's, ICON, Endocyte, BioScrip, and DepoMed
PR Newswire - Mon Apr 07, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Dr. Reddy's Laboratories Ltd. (NYSE: RDY), ICON plc (NASDAQ: ICLR), Endocyte, Inc. (NASDAQ: ECYT), BioScrip Inc. (NASDAQ: BIOS), and DepoMed Inc. (NASDAQ: DEPO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Endocyte Announces Presentations at AACR Annual Meeting 2014
GlobeNewswire - Fri Apr 04, 7:17AM CDT
Endocyte, Inc. (Nasdaq:ECYT) a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that three posters will be presented by Endocyte scientists at the 2014 Annual Meeting of the American Association for Cancer Research (AACR) to be held in San Diego, April 5-9, 2014.

Can Endocyte (ECYT) Run Higher on Strong Earnings Estimate Revisions? (revised) - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 12:06PM CDT
Not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.

Can Endocyte (ECYT) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 7:47AM CDT
Endocyte, a biopharmaceutical company, could be a solid choice for investors, as it has witnessed solid activity on the earnings estimate revision front and the company also has a favorable Zacks Rank.

Endocyte, Inc. Closes Public Offering of Common Stock
GlobeNewswire - Wed Apr 02, 3:01PM CDT
Endocyte, Inc. (Nasdaq:ECYT) announced today the closing of its previously announced underwritten public offering of 5,175,000 shares of its common stock at a price to the public of $21.00 per share, which includes the exercise in full by the underwriters of their option to purchase 675,000 additional shares. Endocyte received net proceeds of approximately $101.8 million from the offering after deducting underwriting discounts and commissions and estimated expenses relating to the offering.

'Mad Money' Lightning Round: Don't Buy eBay
at The Street - Tue Apr 01, 5:00AM CDT
Cramer says he's disappointed by Volaris, missed on Endocyte but likes GNC Holdings and Chicago Mercantile Exchange.

Jim Cramer's 'Mad Money' Recap: Out With a Bang
at The Street - Mon Mar 31, 7:01PM CDT
Cramer says the only thing shocking about Michael Lewis' new book on high-frequency trading is that people find it shocking at all.

Big Pharma Failure = Biotech Takeover?
David Williamson, The Motley Fool - Motley Fool - Mon Mar 31, 5:33PM CDT
Today's big winner in biotech was Endocyte , up 7% on a case of schadenfreude. Its potential big pharma competitor GlaxoSmithKline decided to withdraw an expanded indication of its kidney cancer drug Votrient into ovarian cancer, because of...

Endocyte Prices New Offering at $21 Per Share - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 3:30PM CDT
Endocyte shares fell 4.8% following the announcement of its intention to issue shares and the pricing of the underwritten public offering of its common stock.

Endocyte (ECYT) Slips After Pricing Share Offering
at The Street - Fri Mar 28, 1:04PM CDT
Endocyte (ECYT) is sliding on Friday after pricing its previously-announced share offering.

Nasdaq stocks posting largest percentage decreases
AP - Fri Mar 28, 12:32PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:

Overall Survival Will Be Critical for Endocyte's Vintafolide
Catherine Shaffer, The Motley Fool - Motley Fool - Fri Mar 28, 8:00AM CDT
Shares of Endocyte nearly doubled overnight when it announced positive results from a Phase IIb trial of vintafolide and docetaxel in non-small cell lung cancer (NSCLC). At the same time, the company reported that Europe's Committee for Medicinal...

Endocyte (ECYT) in Focus: Stock Tumbles 8.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 7:47AM CDT
Endocyte, Inc. (ECYT) saw a big move last session, reversing the recent trend for ECYT as the stock is now up more than 75.0% in the past one-month time frame.

Endocyte, Inc. Prices Public Offering of Common Stock
GlobeNewswire - Thu Mar 27, 5:49PM CDT
Endocyte, Inc. (Nasdaq:ECYT) announced the pricing of an underwritten public offering of 4,500,000 shares of its common stock at a price to the public of $21.00 per share. The gross proceeds to Endocyte from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Endocyte, will be approximately $94.5 million. Endocyte has also granted the underwriters a 30-day option to purchase up to an additional 675,000 shares of common stock. The offering is expected to close on or about April 2, 2014, subject to customary closing conditions. Endocyte anticipates using the net proceeds from the offering for working capital and general corporate purposes, including without limitation research and development expenses, including clinical trial costs, capital expenditures and general and administrative expenses.

Will Vintafolide Approval Silence Endocyte Bears?
Cory Renauer, The Motley Fool - Motley Fool - Wed Mar 26, 1:38PM CDT
Unless you've been asleep for a week, you probably noticed that Endocyte shot up over 150% last Friday, before settling near a 100% gain. Nearly two years ago Merck made a deal with Endocyte potentially worth $1 billion. The uncommonly big deal...

Biotech Stock Roundup: GILD Letter Triggers Major Selloff - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 9:13AM CDT
Are the good days over for the biotech sector or is this just a correction?
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bacterial Breakthrough in Cancer Therapy: Game Changer?

Updated Category News Views 35

Blurring Lines Between Bugs and Biotech Well, wouldn't you know it, the eggheads over at Jeonbuk National University in South Korea are at it again, pushing the boundaries of what these little bacterial buggers can do. This time, they’ve had a crack at cancer therapy, using engineered Salmonella to pack a double punch against breast cancer in mice. Now, if that ain't...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 234

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 147

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Medtronic's Bold Move to Own Carotid Market Full-Scale

Updated Category News Views 143

When a giant like Medtronic makes a move, you can bet investors take notice, and this latest acquisition is no exception. They’re reaching into their deep pockets to acquire Contego Medical, a company shaking up the world of carotid artery disease treatments. It’s a tactical strike to solidify their leadership in cardiovascular solutions. Medtronic's Bet on Innovation...

Continue Reading
Webull Faces FINRA Fine and Legal Battle Ahead

Updated Category News Views 45

Webull's Compliance Headache Webull’s been knocked around again. This time, the Financial Industry Regulatory Authority (FINRA) slapped it with a hefty $4.2 million fine. Talk about a hit to the wallet! It all boils down to them failing to roll out some basic anti-money laundering (AML) and other crucial compliance programs. This is no small oversight, and it's got...

Continue Reading
Gwen Stefani Kicks Off OCVIBE's New Concert Hall

Updated Category News Views 116

A Homecoming Steeped in Nostalgia Orange County’s about to do a serious throwback, folks! Gwen Stefani is set to headline the opening concert at OCVIBE's spanking new concert hall in Anaheim on March 17, 2027. Curious choice for their opener? Hardly. This gal's practically woven into the county’s tapestry—her roots run deep here, enough to make even the casual music...

Continue Reading
Mining Equipment Market to Surge, Hitting $42.81B by 2033

Updated Category News Views 98

Forecasts on Market Growth: A Robust Climb Ahead Brace yourself because this mining equipment racket is ramping up like you wouldn't believe. Analysts are telling us the market's supposed to roar from a $28.42 billion check in 2026 to a jaw-dropping $42.81 billion come 2033. That's a 6.0% CAGR—a figure that'll catch the eye of anyone not sound asleep at the wheel....

Continue Reading
WHP Global's Japan Move: A Major Toy Market Play

Updated Category News Views 35

New Horizons for Toys"R"Us in Japan Well, folks, look who's back in the toy game with a vengeance! WHP Global is shaking hands with Pan Pacific International Holdings (PPIH) to breathe new life into Toys"R"Us across Japan. Now PPIH isn’t just any player. We're talking about Japan's fourth-largest retailer, helming giants like Don Quijote and aiming to crown itself as...

Continue Reading
Lear Gears Up for Goldman Sachs Event Spotlight

Updated Category News Views 10

Lear Prepares for the Big Stage in London Autumn leaves and industry insights are falling in full swing as Lear Corporation gets its ducks in a row for the upcoming Goldman Sachs 18th Annual Industrials & Autos Week. Kicking off on December 3, 2026, this gathering in London isn't just another checkbox on their corporate calendar—it's a prime moment in the spotlight....

Continue Reading
Ballard's Q3 2026: Navigating Losses and Bold Moves

Updated Category News Views 80

Ballard’s Financial Puzzles in Q3 2026 Riding the rough waters of the third quarter in 2026, Ballard Power Systems set out its stall with some eyebrow-raising numbers. This ain't the bustling diner vibe we normally see for a thriving business. The results paint a cautious picture sprinkled with strategic shifts that demand a keen eye. GeoPura Acquisition: A Strategic...

Continue Reading

Top 5 Most Recently Viewed Articles

U.S. Industrial Production Unexpectedly Declines, Impacting Growth

Updated Category News Views 62

U.S. Industrial Production Experiences a Notable Decline The latest report reveals that U.S. industrial production has faced an unexpected decline, recorded at -0.3%. This drop highlights the ongoing struggles within the manufacturing, mining, and utility sectors. Disappointing Performance Against Expectations When comparing the -0.3% figure to a predicted decrease of...

Continue Reading
MAXHUB Partners with Microsoft to Enhance Teams Rooms Experience

Updated Category News Views 363

MAXHUB Collaborates with Microsoft to Enhance Teams In an exciting development within the tech landscape, MAXHUB is teaming up with Microsoft in an initiative aimed at improving the security and reliability of Microsoft Teams Rooms. This partnership aligns with MAXHUB's vision of leading in integrated commercial display and unified communications solutions, providing...

Continue Reading
US Dollar Strengthens While Global Markets Face Turmoil

Updated Category News Views 486

US Dollar's Rise Amid Trade Tensions In an unexpected turn of events, the US dollar has extended its gains following President Trump's announcement of new tariffs. As the global markets react to these developments, we dive into the implications for various economies and asset classes. The latest updates indicate that the 25% tariffs on imports from Canada and Mexico,...

Continue Reading
Understanding Your Rights as a Perrigo Company Shareholder

Updated Category News Views 135

Understanding Your Rights as a Perrigo Company Shareholder Shareholders of Perrigo Company plc (NYSE: PRGO) should stay informed about recent developments regarding potential securities law violations. The underlying issues stem from allegations that the company misled investors regarding its infant formula business, which has drawn significant scrutiny. Allegations...

Continue Reading
Spring Surprises: White Castle Unveils Exciting Deals Ahead

Updated Category News Views 521

Spring Promotions at White Castle As the season transforms, White Castle, the pioneering fast-food restaurant known for its Original Slider, unveils enticing deals for its loyal customers. Embracing longer days and warmer weather, the company is determined to deliver exceptional savings for all cravings this spring. Celebrating with Value-Driven Offers White Castle is...

Continue Reading